Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus VAGISTAT 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus VAGISTAT 1.
GYNE-LOTRIMIN 3 vs VAGISTAT-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Tioconazole is an imidazole antifungal that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and fungal growth.
Intravaginal: one applicatorful (5 g of 2% cream) or one suppository (200 mg) once daily at bedtime for 3 days.
One 300 mg vaginal suppository administered as a single dose.
None Documented
None Documented
Terminal elimination half-life is 3.5–5 hours for topical administration; systemic absorption is minimal (<0.5%), so half-life reflects local clearance.
The terminal elimination half-life is approximately 5-7 days, reflecting prolonged vaginal retention and slow systemic absorption.
Clotrimazole is primarily excreted via feces (biliary elimination) as metabolites, with approximately 0.5% excreted renally as unchanged drug.
Approximately 50% is excreted unchanged in feces via biliary elimination; less than 1% is excreted unchanged in urine.
Category C
Category C
Azole Antifungal
Azole Antifungal